Artificial intelligence (AI) approaches have the potential to affect several facets of cancer therapy. These include drug discovery and development and how these drugs are clinically validated and ultimately administered at the point of care, among others. Currently, these processes are expensive and time-consuming. Moreover, therapies often result in variable treatment outcomes between patients. The convergence of AI and cancer therapy has resulted in multiple solutions to address these challenges. AI platforms ranging from machine learning to neural networks can accelerate drug discovery, harness biomarkers to accurately match patients to clinical trials, and truly personalize cancer therapy using only a patient’s own data. These advances are indicators that practice-changing cancer therapy empowered by AI may be on the horizon.
In the SYNERGY-AI study (NCT03452774), virtual tumor boards, which enable clinician teams to provide remote treatment guidance and diagnosis …
The original article can be found at: https://science.sciencemag.org/
Science 28 Feb 2020:
Vol. 367, Issue 6481, pp. 982-983
DOI: 10.1126/science.aaz3023
Article author:Dean HoThe N.1 Institute for Health (N.1), Institute for Digital Medicine (WisDM), Department of Biomedical Engineering, and Department of Pharmacology, National University of Singapore, Singapore.
